vs

Side-by-side financial comparison of Ensysce Biosciences, Inc. (ENSC) and Vuzix Corp (VUZI). Click either name above to swap in a different company.

Vuzix Corp is the larger business by last-quarter revenue ($2.2M vs $1.9M, roughly 1.2× Ensysce Biosciences, Inc.). Ensysce Biosciences, Inc. runs the higher net margin — -147.0% vs -384.2%, a 237.1% gap on every dollar of revenue. On growth, Vuzix Corp posted the faster year-over-year revenue change (76.4% vs 44.4%). Over the past eight quarters, Ensysce Biosciences, Inc.'s revenue compounded faster (107.9% CAGR vs 5.8%).

Ensysce Biosciences, Inc. is a clinical-stage biotechnology firm specializing in developing innovative prodrug therapies for pain management and oncology indications. Its proprietary platform is designed to reduce opioid abuse risks while enhancing treatment efficacy, targeting global healthcare and pharmaceutical markets with a focus on unmet clinical needs.

Vuzix Corporation is an American multinational technology company headquartered in Rochester, New York and founded by Paul Travers in 1997. Vuzix is a supplier of smartglasses and augmented reality display technology. Vuzix manufactures and sells computer display devices and software. Vuzix head-mounted displays are marketed towards mobile and immersive augmented reality applications, such as 3D gaming, manufacturing training, and military tactical equipment. On January 5, 2015, Intel acquire...

ENSC vs VUZI — Head-to-Head

Bigger by revenue
VUZI
VUZI
1.2× larger
VUZI
$2.2M
$1.9M
ENSC
Growing faster (revenue YoY)
VUZI
VUZI
+32.0% gap
VUZI
76.4%
44.4%
ENSC
Higher net margin
ENSC
ENSC
237.1% more per $
ENSC
-147.0%
-384.2%
VUZI
Faster 2-yr revenue CAGR
ENSC
ENSC
Annualised
ENSC
107.9%
5.8%
VUZI

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ENSC
ENSC
VUZI
VUZI
Revenue
$1.9M
$2.2M
Net Profit
$-2.8M
$-8.6M
Gross Margin
16.7%
Operating Margin
-147.8%
-373.9%
Net Margin
-147.0%
-384.2%
Revenue YoY
44.4%
76.4%
Net Profit YoY
22.3%
36.9%
EPS (diluted)
$-0.51
$-0.12

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ENSC
ENSC
VUZI
VUZI
Q4 25
$1.9M
$2.2M
Q3 25
$493.1K
$1.2M
Q2 25
$1.4M
$1.3M
Q1 25
$1.3M
$1.6M
Q4 24
$1.3M
$1.3M
Q3 24
$3.4M
$1.4M
Q2 24
$1.1M
Q1 24
$2.0M
Net Profit
ENSC
ENSC
VUZI
VUZI
Q4 25
$-2.8M
$-8.6M
Q3 25
$-3.7M
$-7.4M
Q2 25
$-1.7M
$-7.7M
Q1 25
$-1.9M
$-8.6M
Q4 24
$-3.6M
$-13.7M
Q3 24
$661.8K
$-9.2M
Q2 24
$-40.6M
Q1 24
$-10.0M
Gross Margin
ENSC
ENSC
VUZI
VUZI
Q4 25
16.7%
Q3 25
-35.4%
Q2 25
-58.7%
Q1 25
-16.8%
Q4 24
-389.6%
Q3 24
-18.8%
Q2 24
-30.5%
Q1 24
-2.6%
Operating Margin
ENSC
ENSC
VUZI
VUZI
Q4 25
-147.8%
-373.9%
Q3 25
-758.7%
-645.5%
Q2 25
-127.6%
-606.1%
Q1 25
-149.1%
-555.0%
Q4 24
-274.3%
-1089.2%
Q3 24
18.9%
-670.9%
Q2 24
-3726.5%
Q1 24
-503.6%
Net Margin
ENSC
ENSC
VUZI
VUZI
Q4 25
-147.0%
-384.2%
Q3 25
-756.3%
-633.4%
Q2 25
-126.4%
-591.5%
Q1 25
-147.4%
-546.4%
Q4 24
-273.4%
-1074.0%
Q3 24
19.4%
-665.4%
Q2 24
-3715.6%
Q1 24
-501.4%
EPS (diluted)
ENSC
ENSC
VUZI
VUZI
Q4 25
$-0.51
$-0.12
Q3 25
$-1.29
$-0.09
Q2 25
$-0.79
$-0.10
Q1 25
$-1.39
$-0.11
Q4 24
$-0.89
$-0.16
Q3 24
$1.00
$-0.14
Q2 24
$-0.62
Q1 24
$-0.16

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ENSC
ENSC
VUZI
VUZI
Cash + ST InvestmentsLiquidity on hand
$4.3M
$21.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$3.2M
$24.7M
Total Assets
$7.5M
$40.1M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ENSC
ENSC
VUZI
VUZI
Q4 25
$4.3M
$21.2M
Q3 25
$1.7M
$22.6M
Q2 25
$2.2M
$17.5M
Q1 25
$3.1M
$15.2M
Q4 24
$3.5M
$18.2M
Q3 24
$4.2M
$14.3M
Q2 24
$9.9M
Q1 24
$16.5M
Stockholders' Equity
ENSC
ENSC
VUZI
VUZI
Q4 25
$3.2M
$24.7M
Q3 25
$1.2M
$27.9M
Q2 25
$3.4M
$28.9M
Q1 25
$3.0M
$32.8M
Q4 24
$3.7M
$37.3M
Q3 24
$6.9M
$39.6M
Q2 24
$35.4M
Q1 24
$73.1M
Total Assets
ENSC
ENSC
VUZI
VUZI
Q4 25
$7.5M
$40.1M
Q3 25
$3.2M
$42.5M
Q2 25
$5.6M
$36.9M
Q1 25
$4.6M
$35.8M
Q4 24
$5.6M
$39.4M
Q3 24
$9.4M
$41.8M
Q2 24
$38.2M
Q1 24
$77.0M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ENSC
ENSC
VUZI
VUZI
Operating Cash FlowLast quarter
$-1.5M
$-5.6M
Free Cash FlowOCF − Capex
$-5.9M
FCF MarginFCF / Revenue
-263.5%
Capex IntensityCapex / Revenue
15.8%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-20.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ENSC
ENSC
VUZI
VUZI
Q4 25
$-1.5M
$-5.6M
Q3 25
$-1.9M
$-5.0M
Q2 25
$-2.7M
$-4.8M
Q1 25
$-1.7M
$-3.5M
Q4 24
$-764.1K
$-4.0M
Q3 24
$-1.0M
$-5.3M
Q2 24
$-5.6M
Q1 24
$-8.8M
Free Cash Flow
ENSC
ENSC
VUZI
VUZI
Q4 25
$-5.9M
Q3 25
$-5.3M
Q2 25
$-5.5M
Q1 25
$-4.1M
Q4 24
$-4.3M
Q3 24
$-5.5M
Q2 24
$-6.5M
Q1 24
$-8.9M
FCF Margin
ENSC
ENSC
VUZI
VUZI
Q4 25
-263.5%
Q3 25
-457.4%
Q2 25
-425.6%
Q1 25
-257.2%
Q4 24
-334.4%
Q3 24
-395.1%
Q2 24
-591.4%
Q1 24
-444.4%
Capex Intensity
ENSC
ENSC
VUZI
VUZI
Q4 25
15.8%
Q3 25
27.4%
Q2 25
56.1%
Q1 25
38.8%
Q4 24
18.1%
Q3 24
14.4%
Q2 24
75.8%
Q1 24
5.1%
Cash Conversion
ENSC
ENSC
VUZI
VUZI
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
-1.54×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons